key: cord-0750195-1lv85pgb
authors: Al Khames Aga, Qutaiba A.; Alkhaffaf, Waseem H.; Hatem, Tagreed H.; Nassir, Kawthar F.; Batineh, Yazan; Dahham, Abdullah T.; Shaban, Dimah; Al Khames Aga, Luma A.; Agha, Manhal Y. R.; Traqchi, Muaamar
title: Safety of COVID‐19 vaccines
date: 2021-07-28
journal: J Med Virol
DOI: 10.1002/jmv.27214
sha: da9c3c9ccf052ed6089df18dc0b361f2a597801f
doc_id: 750195
cord_uid: 1lv85pgb

This study is aimed to identify the adverse effects associated with three types of coronavirus disease 2019 vaccines. Approximately 1736 individuals agreed to participate in this study. The participants involved in the study were individuals who had received the first dose or full course (two doses) of the vaccine at least 30 days before the survey. A direct and interactive web‐based system interview with a paper and electronic version of the questionnaire was used for all participants. A total of 1736 randomized individuals were identified. The reactogenicity of the vaccines including pain, redness, urticaria, and swelling at the site of the injection was reported in 34.56% of the participants. Local site reaction was reported in more individuals who had Pfizer and AstraZeneca vaccines than those who received the Sinopharm vaccine. The systemic events were more common with AstraZeneca and Pfizer vaccines, symptoms reported were fatigue, body pain, headache, muscle pain, fever, and gastrointestinal side effects. There were no correlations between age or gender, and the duration of the adverse effects for the three vaccines. Swelling and severe allergic reaction of the eyelids, severe hypotension, generalized body aches, shortness of breath, weakness and numbness on the injected arm, acute hyperglycemia, severe chest pain, and fever more than 39°C were among the unusual signs and symptoms reported by the participants. Pfizer, AstraZeneca, and Sinopharm vaccines were found to be safe and Sinopharm vaccine showed a lower prevalence of adverse effects compared with the other vaccines. The duration and severity of adverse effects were not affected by age or gender. Unusual side effects should be closely monitored to establish determine they are linked to the immunization.

The United States has approved the use of two coronavirus disease 2019 (COVID- 19) vaccines. 1 The Food and Drug Administration granted an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine on December 11, 2020, and on December 18, 2020, for the Moderna COVID-19 vaccine; both are to be given in a two-dose sequence. 2 According to Reuters, Phase III trials for the Sinopharm shot took place in 10 countries around the world in September 2020. China and some other countries, including Jordan, have approved the Sinopharm vaccine. 3 These vaccines have been modeled in different development approaches, therefore they have diversity in some characteristics like efficacy and storage conditions. 4 The Pfizer and Moderna vaccines are nucleic acid vaccines that use genetic materials such as messenger RNA, or mRNA, a technology that gets part of genetic code into the human cells. Sinopharm, on the other hand, is BBIBP-CorV, an inactivated coronavirus vaccine. 5 The immune response is triggered to produce antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus by BBIBP-CorV. Antibodies bind to viral proteins like the spike proteins that stud the virus's surface.

Safety monitoring for these vaccines is an essential Phase IV clinical study despite thousands of participants were involved in the clinical Phase II and III trials. At the time of writing, the number of people vaccinated was 411.61 million and 93,343,417 are fully vaccinated globally. 6 For a good reason, vaccine production is a lengthy and timeconsuming process. Vaccines are typically given to large groups of healthy people to avoid infection rather than to give them to sick people to help them recover. Therefore, a new vaccine's protection threshold must be very high and apply to the entire target population, regardless of age, gender, color, or ethnicity. 7 Individuals would not consider taking a vaccine because of its side effects when it is meant to protect them from contracting the infection. The careful and deliberate method of vaccine's production and testing is guided by this central emphasis on protection. Phase 4 trials, which include hundreds of thousands of people and concentrate on vaccine's safety (how well the vaccine performs in the real world), as well as monitoring for rare adverse effects, are done after the vaccine has been licensed. 8 There was no evidence of a causal association between COVID-19 vaccines and death, this was based on records collected from death certificates, autopsy reports, psychiatric history, and clinical descriptions from VAERS reports and healthcare providers. Only a few cases of anaphylaxis have been identified after receiving Pfizer-BioNTech and Moderna COVID-19 vaccines (4.5 reported cases per million doses administered). 9 Reactions registered to the v-safe system by people who had received the Pfizer-BioNTech vaccine were more common after administering the second dose than after the first. The two COVID-19 vaccines currently in use did not show any signs of unexpected significant adverse effects in their original postauthorization protection profiles. 10 These findings provide reassurance and insights on what healthcare providers and vaccinated individuals should predict after vaccination.

This study involved 1736 participants with the age range of years. The participants included in the study were people who had taken the first dose or full course of vaccine (two doses) a minimum of 30 days before the study. Moreover, participants subgrouped into those who had taken either Pfizer, AstraZeneca, or Sinopharm vaccine. A trained research assistant conducted a direct interview with a paper version of the questionnaire and an interactive web-based system interview with an electronic version of the questionnaire for the participants. The questionnaire collected information such as the participants' demographic data (age, gender, weight, and smoking); comorbidities (cardiovascular, respiratory, kidney, liver, immunological, and endocrine diseases); type of vaccine received, number of vaccine doses; and the symptoms the individuals presented with after the vaccination and the duration of these symptoms. The prevalence of these adverse reactions was analyzed and assessed to determine what symptoms are the most common and to what type of vaccine could be associated with. The prevalence of signs and symptoms were expressed as a number and percentage and mean ± SD was used to describe the continuous variables. Analysis of variance test used to compare the dependent variables. Hazard ratio and 95% confidence interval used to determine the risk of age and gender with the duration and prevalence of the signs and symptoms.

For the period from January 1, 2021 to April 10, 2021, a total of 1736 randomized participants from Iraq and Jordan have been identified for the study, of whom 700 received Pfizer (BioNTech) vaccine, 696 received AstraZeneca (AZD1222), and 340 received Sinopharm (BBIBP-CorV). The demographic data for these participants were illustrated in Table 1 

The reactogenicity of vaccines including pain, redness, urticaria, and swelling at the site of the injection was reported by 34.56% of participants. Overall, Pfizer and AstraZeneca recipients reported more local reactions at the site of the injection than those who received Sinopharm vaccine with an average duration of 2 days (Table 2 and Figure 1 ).

Signs and symptoms after the first dose of AstraZeneca vaccine were more prevalent compared with other vaccines, followed by Pfizer and less adverse reaction associated with Sinopharm vaccine (Table 3 and Figure 2 ).

Despite the fact that a small number of participants received a second dose of AstraZeneca vaccine, the signs and symptoms were more prevalent with the second dose compared to Pfizer and Sinopharm vaccines (Table 3 and Figure 3 ). The duration of signs and symptoms was not affected by age and gender in the three types of vaccines (Tables 1 and 2 ). Side effects are natural reactions to foreign drug injection, these include symptoms such as fever, muscle pain, and inflammation at the site of injection. They are mediated by the innate immune system. When the body's neutrophils or macrophages detect vaccine molecules, they release cytokines, which are chemical signals that trigger immune responses expressed as fever, chills, nausea, and muscle pain. This cytokines' reaction is expected to occur when a foreign agent is inserted into the bloodstream. 16 About half of people aged 16-55 who got a SARS-CoV-2 vaccine experienced a headache after the second dose according to trials when neither the recipients nor the researchers had the knowledge of who got a placebo and who got the mRNA vaccine. This reaction may relate to the vaccine. 17 Blood clots, which lead the United States to halt the AstraZeneca vaccine, are a very unusual occurrence, reportedly occurring one in a million times. Blood clots are currently being investigated as a possible side effect of the vaccine, yet a link to be found, they will be an incredibly unlikely complication. 18 According to scientists, there is no connection between the initial inflammatory reaction and the long-term defensive response. There is no scientific indication that those with more noticeable vaccine side effects are better protected from COVID-19. There's no reason to think that an exaggerated innate response will help the adaptive response. 19 This study was not designed to assess the efficacy of these vaccines, Following the initiation of these vaccinations, reports of anaphylaxis have been submitted. During the analytic era, the incidence of anaphylaxis after receiving COVID-19 vaccines was within the range for the data recorded after receiving inactivated influenza vaccine, pneumococcal polysaccharide vaccine, and live attenuated herpes zoster vaccine; successful medications for anaphylaxis are available. 9 Reactogenicity was generally mild or moderate, and reactions were less common and milder in participants who had Sinopharm vaccine compared to Pfizer and AstraZeneca vaccine. In a double-blind, randomized, placebo-controlled clinical trial performed in Henan Province, China, the average cumulative adverse events recorded after 7 days of Sinopharm vaccine for Phases 1 and 2 were 15%. 20 In our study, overall Sinopharm vaccination's adverse effect was ranged between 1.18% with loss of smell and test to 27.06% with a headache.

Fatigue, headache, body pain, and muscle pain were among the most common adverse effects associated with the three vaccines.

AstraZeneca was associated with higher prevalence; this is compatible with other studies.

One of the study limitations was the number of participants who administered the second dose of vaccine. Generally, the first dose of the vaccine showed a higher prevalence of adverse effects with AstraZeneca vaccine, followed by Pfizer and was less with Sinopharm. Despite a small number of participants received the second dose of AstraZeneca vaccine, the adverse effect was still higher compared with the other two vaccines.

Though, fatigue, body pain, and reactogenicity were higher prevalent after the second dose of Pfizer vaccine. This, however, requires further investigation with large-scale participants.

Although age was not significantly shown to affecting the duration and severity of the adverse effect of the three types of vaccines, the duration was longer in participants over 55 years old who received As-traZeneca and Sinopharm vaccine. With regards to the Pfizer vaccine, the duration was relatively higher in participants aged between 36 and 55.

This conclusion could be resulted from the small number of elderly participants recruited for the study who administered Pfizer vaccine.

Furthermore, females suffered from adverse effects with longer duration compared to male counterparts after receiving one of the three vaccines.

In this study we reported unusual events that could be related to the vaccines like swelling and severe allergic reaction of eyelids, hospital admission due to positive results for COVID-19 infection, weakness and numbness of the hand of the injected arm, severe chest pain, nasal bleeding, acute hypertension with blood pressure over 210/105 mm Hg, and acute hyperglycemia (FBS > 170 mg/dL). These events were most evident with Pfizer and AstraZeneca vaccines and only one case was reported with Sinopharm vaccine. Since untoward cases might occur independently of vaccination, we must closely review any case of adverse effect after vaccination, paying particular attention to the "base incidence" of that event in the community before vaccination.

Pfizer, AstraZeneca, and Sinopharm vaccines were found to be safe according to the observation of the mild to moderate postvaccination signs and symptoms. Sinopharm vaccine showed a lower prevalence of adverse effects compared with Pfizer and AstraZeneca vaccine after first and second dose respectively. Age and gender

were not significantly affecting the duration and severity of adverse effects. Unusual adverse effects should be monitored carefully to determine whether they are related to the vaccine or not.

A global survey of potential acceptance of a COVID-19 vaccine

Clinical outcomes of a COVID-19 vaccine: implementation over efficacy: study examines how definitions and thresholds of vaccine efficacy, coupled with different levels of implementation effectiveness and background epidemic severity, translate into outcomes

COVID-19: insights into potential vaccines

Phage display as a promising approach for vaccine development

Repurposed drugs, molecular vaccines, immune-modulators, and nanotherapeutics to treat and prevent COVID-19 associated with SARS-CoV-2, a deadly nanovector

Viruses that can and cannot coexist with humans and the future of SARS-CoV-2

Vaccine safety, efficacy, and trust take time

Vaccines: The Biggest Medical Fraud in History

First month of COVID-19 vaccine safety monitoring-United States

The impact of increasing prevalence, false omissions, and diagnostic uncertainty on coronavirus disease 2019 (COVID-19) test performance

Current progress and challenges in the design and development of a successful COVID-19 vaccine

Pharmacists as Immunizes: Increasing Non-influenza Adult Immunization Rates

Opinion: For now, it's unethical to use human challenge studies for SARS-CoV-2 vaccine development

Vaccine safety evaluation: practical aspects in assessing benefits and risks

Structure and function of COVID-19 Encode Proteins In The Transcription And Replication Mechanism With Its Preventive Measures And Propose Efficacy Treatments: A Critical Systematic Review

Infusion reactions: diagnosis, assessment, and management

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

COVID-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots

No, vaccine side effects don't tell you how well your immune system will protect you from COVID-19

Adverse events reported from COVID-19 vaccine trials: a systematic review

How to cite this article: Al Khames Aga QA

Safety of COVID-19 vaccines

The authors would like to thank all participants for their participation. Authors' received no financial support for the research, authorship, or publication of this article.

The authors declare that there are no conflict of interests.

All participants enrolled in the study signed their written consent forms before participating in the study and give an agreement to use their results. The study was approved by the ethical committee of